We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-18.54%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.69B
AUM Growth
-$959M
Cap. Flow
-$224M
Cap. Flow %
-13.27%
Top 10 Hldgs %
79.99%
Holding
63
New
4
Increased
11
Reduced
6
Closed
17
Avg Time Held Equity + Options
7.5 quarters
Top 10 Avg Time Held Equity + Options
6.6 quarters
Top 20 Avg Time Held Equity + Options
8 quarters
Avg Time Held Equity only
7.7 quarters
Top 10 Avg Time Held Equity only
6.6 quarters
Top 20 Avg Time Held Equity only
8 quarters

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$55M
2
ZYME icon
Zymeworks
ZYME
+$30.4M
3
AKRO icon
Akero Therapeutics
AKRO
+$18.7M
4
BEAM icon
Beam Therapeutics
BEAM
+$13.8M
5
QURE icon
uniQure
QURE
+$8.26M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$129M
2
SWTX icon
SpringWorks Therapeutics
SWTX
+$56.4M
3
THRD icon
Third Harmonic Bio
THRD
+$32.7M
4
NMRA icon
Neumora Therapeutics
NMRA
+$22M
5
CRGX icon
CARGO Therapeutics
CRGX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
2 Miscellaneous 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APLS icon
1
DELISTED
Apellis Pharmaceuticals
APLS
$260M 15.43%
11,895,808
+4,965
+0% +$137K
2021 Q4
13 quarters
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$13.7B
$212M 12.57%
1,706,469
– –
2023 Q2
7 quarters
ZYME icon
3
Zymeworks
ZYME
$1.8B
$206M 12.19%
17,259,548
+2,231,469
+15% +$30.4M
2022 Q4
9 quarters
ANAB icon
4
AnaptysBio
ANAB
$1.36B
$146M 8.69%
7,880,094
+6,646
+0.1% +$111K
2019 Q4
21 quarters
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$144M 8.53%
4,288,120
– –
2021 Q4
13 quarters
PRTA icon
6
Prothena Corp
PRTA
$429M
$143M 8.5%
11,584,280
– –
2018 Q4
25 quarters
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.74B
$82.5M 4.89%
1,292,386
+522,386
+68% +$55M
2024 Q4
1 quarter
XNCR icon
8
Xencor
XNCR
$1.75B
$65.4M 3.88%
6,144,767
– –
2018 Q4
25 quarters
CRSP icon
9
CRISPR Therapeutics
CRSP
$4.84B
$47.3M 2.8%
1,389,276
– –
2024 Q1
4 quarters
QURE icon
10
uniQure
QURE
$1.48B
$42.3M 2.51%
3,988,971
+588,971
+17% +$8.26M
2024 Q4
1 quarter
JANX icon
11
Janux Therapeutics
JANX
$1.05B
$39.7M 2.35%
1,469,818
– –
2024 Q2
3 quarters
IMNM icon
12
Immunome
IMNM
$2.07B
$27.5M 1.63%
4,079,415
+200,000
+5% +$1.92M
2023 Q4
5 quarters
ETON icon
13
Eton Pharmaceutcials
ETON
$1.52B
$25.2M 1.49%
1,939,288
+109,685
+6% +$1.66M
2024 Q3
2 quarters
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$10.4B
$24.8M 1.47%
75,000
– –
2024 Q1
4 quarters
ORIC icon
15
Oric Pharmaceuticals
ORIC
$1.17B
$19.1M 1.13%
3,418,068
– –
2020 Q2
19 quarters
AKRO icon
16
DELISTED
Akero Therapeutics
AKRO
$17.8M 1.06%
+440,000
New +$18.7M
2025 Q1
0 quarters
KURA icon
17
Kura Oncology
KURA
$874M
$17.4M 1.03%
2,640,298
-916,971
-26% -$7.15M
2015 Q4
37 quarters
TECX icon
18
Tectonic Therapeutic
TECX
$417M
$16.6M 0.98%
935,121
+85,978
+10% +$2.8M
2024 Q2
3 quarters
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$16.5M 0.98%
557,576
– –
2024 Q1
4 quarters
NGNE icon
20
Neurogene
NGNE
$431M
$14.9M 0.88%
1,271,342
– –
2023 Q4
5 quarters
TNGX icon
21
Tango Therapeutics
TNGX
$3.75B
$14.6M 0.86%
10,630,736
– –
2020 Q3
18 quarters
VYGR icon
22
Voyager Therapeutics
VYGR
$132M
$13.2M 0.79%
3,917,546
– –
2021 Q3
14 quarters
BEAM icon
23
Beam Therapeutics
BEAM
$2.52B
$10.3M 0.61%
+526,685
New +$13.8M
2025 Q1
0 quarters
MBX icon
24
MBX Biosciences
MBX
$2.36B
$9.29M 0.55%
1,259,273
– –
2024 Q3
2 quarters
DNA icon
25
Ginkgo Bioworks
DNA
$792M
$8.34M 0.49%
1,462,328
-281,016
-16% -$2.86M
2024 Q4
1 quarter
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2025 Portfolio in Review

As of Q1 2025, EcoR1 Capital held 63 positions worth $1.69B, down 36% from $2.65B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

EcoR1 Capital withdrew a net $224M in Q1 2025, closing 17 positions and reducing 6 holdings. Its most notable exit was Arvinas, an estimated $129M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Akero Therapeutics worth $17.8M.

  • EcoR1 Capital's largest Q1 2025 buy was Akero Therapeutics: 440,000 shares worth $17.8M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q1 2025, an estimated $55M increase.
  • EcoR1 Capital's biggest Q1 2025 reduction was TScan Therapeutics, cutting an estimated $9.38M.
  • EcoR1 Capital fully exited Arvinas in Q1 2025, selling an estimated $129M.
  • EcoR1 Capital's ten largest holdings make up 80% of its $1.69B portfolio in Q1 2025.
  • EcoR1 Capital opened 4 new positions and closed 17 in Q1 2025.
  • EcoR1 Capital's portfolio value fell 36% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.